Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2017 2
2019 5
2020 3
2021 2
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Current recommendations and recent progress in endometrial cancer.
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Brooks RA, et al. Among authors: veneris jl. CA Cancer J Clin. 2019 Jul;69(4):258-279. doi: 10.3322/caac.21561. Epub 2019 May 10. CA Cancer J Clin. 2019. PMID: 31074865 Free article. Review.
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Oaknin A, et al. Among authors: veneris j. J Immunother Cancer. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777. J Immunother Cancer. 2022. PMID: 35064011 Free PMC article. Clinical Trial.
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV. Oaknin A, et al. Among authors: veneris j. Clin Cancer Res. 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. Clin Cancer Res. 2023. PMID: 37363992 Free PMC article.
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C 3rd, Dong Y, Veneris J, Pothuri B. Oaknin A, et al. Among authors: veneris j. Future Oncol. 2023 Aug;19(25):1709-1714. doi: 10.2217/fon-2022-1157. Epub 2023 Jun 29. Future Oncol. 2023. PMID: 37381977 Free article. Review.
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, Ellard S, de Braud F, Arkenau HT, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano YA, Samouëlian V, Miller R, Boni V, Torres AA, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. André T, et al. Among authors: veneris j. JAMA Netw Open. 2023 Nov 1;6(11):e2341165. doi: 10.1001/jamanetworkopen.2023.41165. JAMA Netw Open. 2023. PMID: 37917058 Free PMC article. Clinical Trial.
Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Pashankar F, et al. Among authors: veneris j. Eur J Cancer. 2022 Sep;173:59-70. doi: 10.1016/j.ejca.2022.06.006. Epub 2022 Jul 18. Eur J Cancer. 2022. PMID: 35863107 Review.
Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen HX, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Corcoran RB, et al. Among authors: veneris j. Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3135. Online ahead of print. Clin Cancer Res. 2024. PMID: 38456660
19 results